A Pivotal Phase III trial of Phaxan, a new formulation of alphaxalone dissolved in sulfobutyl ether beta cyclodextrin, for anaesthesia in patients undergoing hip joint replacement; stage 1, the pilot study

Trial Profile

A Pivotal Phase III trial of Phaxan, a new formulation of alphaxalone dissolved in sulfobutyl ether beta cyclodextrin, for anaesthesia in patients undergoing hip joint replacement; stage 1, the pilot study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Alfaxalone (Primary) ; Propofol; Sevoflurane
  • Indications Anaesthesia
  • Focus Adverse reactions
  • Acronyms PHAXTIVA
  • Sponsors Drawbridge Pharmaceuticals
  • Most Recent Events

    • 13 Apr 2018 Planned initiation date changed from 1 Feb 2018 to 6 Apr 2018.
    • 13 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 18 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top